Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK239512 for cognitive impairment in schizophrenia
NCT01009060Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2009
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gsk239512 in schizophrenia, sponsored by GSK. Started Dec 2009; status: completed.
02
Drugs
gsk239512
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01009060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01009060.